Ads
related to: takeda co pay assistance program biktarvy- Patient Stories
See Patient Testimonials
About BIKTARVY®. Learn More Today.
- What's In BIKTARVY®?
Learn What's Inside BIKTARVY®
& Find Out How It Works
- How To Take BIKTARVY®
Take BIKTARVY® Exactly As Your
Healthcare Provider Directs
- Learn About BIKTARVY®
Discover Info About BIKTARVY®
At The Official Patient Site
- Patient Stories
Search results
Results from the WOW.Com Content Network
Bictegravir (BIC) is an integrase strand transfer inhibitor (INSTI). Bictegravir is different from other INSTIs because it contains a bridged bicyclic ring and a distinct benzyl tail with a 2,4,6-trifluorobenzyl group.
The insurance benefit manager recognizes the drug as a TIER 3 brand for the patient and relays the patient co-pay to be $30.00. The co-pay card benefit manager recognizes the $30.00 and covers the $20.00 of co-pay, leaving $10 for the patient to pay out of pocket. Another patient without prescription insurance coverage follows the same process.
Bictegravir (INN; BIC, formerly known as GS-9883) [1] [2] is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Under terms of the amendment, Takeda will pay Wave $22.5 million for collaboration-related research and preclinical expenses. The amendment allows Wave to advance or partner CNS programs ...
Gilead announced a Phase III clinical trial evaluating a single-tablet regimen combining tenofovir alafenamide with cobicistat, emtricitabine and elvitegravir [44] and developed a coformulation of the drug with cobicistat, emtricitabine and the protease inhibitor darunavir.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code
Ads
related to: takeda co pay assistance program biktarvy